Matsuzawa Yasushi, Guddeti Raviteja R, Kwon Taek-Geun, Lerman Lilach O, Lerman Amir
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Prog Cardiovasc Dis. 2015 Mar-Apr;57(5):431-42. doi: 10.1016/j.pcad.2014.10.004. Epub 2014 Oct 22.
Ischemic heart disease is the leading cause of morbidity and mortality throughout the world. Many clinical trials have suggested that lifestyle and pharmacologic interventions are effective in attenuating atherosclerotic disease progression and events development. However, an individualized approach with careful consideration to comprehensive vascular health is necessary to perform successful intervention strategies. Endothelial dysfunction plays a pivotal role in the early stage of atherosclerosis and is also associated with plaque progression and occurrence of atherosclerotic complications. The assessment of endothelial function provides us with important information about individual patient risk, progress and vulnerability of disease, and guidance of therapy. Thus, the application of endothelial function assessment might enable clinicians to innovate ideal individualized medicine. In this review, we summarize the current knowledge on the impact of pharmacological therapies for atherosclerotic cardiovascular disease on endothelial dysfunction, and argue for the utility of non-invasive assessment of endothelial function aiming at individualized medicine.
缺血性心脏病是全球发病和死亡的主要原因。许多临床试验表明,生活方式和药物干预在减缓动脉粥样硬化疾病进展和事件发生方面是有效的。然而,要实施成功的干预策略,需要采取个性化方法并仔细考虑全面的血管健康状况。内皮功能障碍在动脉粥样硬化的早期阶段起关键作用,并且还与斑块进展和动脉粥样硬化并发症的发生有关。内皮功能评估为我们提供了有关个体患者风险、疾病进展和易损性以及治疗指导的重要信息。因此,内皮功能评估的应用可能使临床医生能够创新理想的个性化医学。在本综述中,我们总结了目前关于动脉粥样硬化性心血管疾病药物治疗对内皮功能障碍影响的知识,并论证了旨在实现个性化医学的内皮功能无创评估的实用性。